SAGIMET BIOSCIENCES INC-A (SGMT) Stock Fundamental Analysis

NASDAQ:SGMT • US7867001049

5.71 USD
-0.16 (-2.73%)
At close: Feb 27, 2026
5.7 USD
-0.01 (-0.18%)
After Hours: 2/27/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall SGMT gets a fundamental rating of 3 out of 10. We evaluated SGMT against 520 industry peers in the Biotechnology industry. While SGMT has a great health rating, there are worries on its profitability. SGMT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • SGMT had negative earnings in the past year.
  • SGMT had a negative operating cash flow in the past year.
  • SGMT had negative earnings in each of the past 5 years.
  • SGMT had a negative operating cash flow in each of the past 5 years.
SGMT Yearly Net Income VS EBIT VS OCF VS FCFSGMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

  • With a Return On Assets value of -44.91%, SGMT perfoms like the industry average, outperforming 53.45% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -48.36%, SGMT is in the better half of the industry, outperforming 66.28% of the companies in the same industry.
Industry RankSector Rank
ROA -44.91%
ROE -48.36%
ROIC N/A
ROA(3y)-49.86%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
SGMT Yearly ROA, ROE, ROICSGMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • SGMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMT Yearly Profit, Operating, Gross MarginsSGMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • SGMT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, SGMT has more shares outstanding
  • There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SGMT Yearly Shares OutstandingSGMT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SGMT Yearly Total Debt VS Total AssetsSGMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 7.89 indicates that SGMT is not in any danger for bankruptcy at the moment.
  • SGMT has a Altman-Z score of 7.89. This is in the better half of the industry: SGMT outperforms 78.54% of its industry peers.
  • There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.89
ROIC/WACCN/A
WACCN/A
SGMT Yearly LT Debt VS Equity VS FCFSGMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 13.06 indicates that SGMT has no problem at all paying its short term obligations.
  • SGMT has a better Current ratio (13.06) than 88.51% of its industry peers.
  • SGMT has a Quick Ratio of 13.06. This indicates that SGMT is financially healthy and has no problem in meeting its short term obligations.
  • SGMT has a Quick ratio of 13.06. This is amongst the best in the industry. SGMT outperforms 88.51% of its industry peers.
Industry RankSector Rank
Current Ratio 13.06
Quick Ratio 13.06
SGMT Yearly Current Assets VS Current LiabilitesSGMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • SGMT shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.09%.
  • SGMT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-4.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -9.38% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.27%
EPS Next 2Y-16.71%
EPS Next 3Y-12.99%
EPS Next 5Y-9.38%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SGMT Yearly Revenue VS EstimatesSGMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
SGMT Yearly EPS VS EstimatesSGMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SGMT. In the last year negative earnings were reported.
  • Also next year SGMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMT Price Earnings VS Forward Price EarningsSGMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMT Per share dataSGMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A cheap valuation may be justified as SGMT's earnings are expected to decrease with -12.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.71%
EPS Next 3Y-12.99%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SGMT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SAGIMET BIOSCIENCES INC-A

NASDAQ:SGMT (2/27/2026, 8:00:02 PM)

After market: 5.7 -0.01 (-0.18%)

5.71

-0.16 (-2.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-12
Inst Owners40.89%
Inst Owner Change5.88%
Ins Owners1.43%
Ins Owner Change2.56%
Market Cap185.69M
Revenue(TTM)N/A
Net Income(TTM)-57.67M
Analysts85
Price Target25.96 (354.64%)
Short Float %11.77%
Short Ratio4.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.24%
Min EPS beat(2)-1.7%
Max EPS beat(2)38.18%
EPS beat(4)3
Avg EPS beat(4)18.78%
Min EPS beat(4)-1.7%
Max EPS beat(4)38.18%
EPS beat(8)5
Avg EPS beat(8)12.31%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.34%
PT rev (3m)-3.34%
EPS NQ rev (1m)3.94%
EPS NQ rev (3m)4.14%
EPS NY rev (1m)0.9%
EPS NY rev (3m)1.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 1.56
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.67
TBVpS3.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.91%
ROE -48.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.86%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.06
Quick Ratio 13.06
Altman-Z 7.89
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
EPS Next Y-19.27%
EPS Next 2Y-16.71%
EPS Next 3Y-12.99%
EPS Next 5Y-9.38%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.55%
EBIT Next 3Y-17.8%
EBIT Next 5YN/A
FCF growth 1Y-78.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.55%
OCF growth 3YN/A
OCF growth 5YN/A

SAGIMET BIOSCIENCES INC-A / SGMT FAQ

What is the ChartMill fundamental rating of SAGIMET BIOSCIENCES INC-A (SGMT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SGMT.


Can you provide the valuation status for SAGIMET BIOSCIENCES INC-A?

ChartMill assigns a valuation rating of 0 / 10 to SAGIMET BIOSCIENCES INC-A (SGMT). This can be considered as Overvalued.


Can you provide the profitability details for SAGIMET BIOSCIENCES INC-A?

SAGIMET BIOSCIENCES INC-A (SGMT) has a profitability rating of 1 / 10.


How financially healthy is SAGIMET BIOSCIENCES INC-A?

The financial health rating of SAGIMET BIOSCIENCES INC-A (SGMT) is 8 / 10.


What is the earnings growth outlook for SAGIMET BIOSCIENCES INC-A?

The Earnings per Share (EPS) of SAGIMET BIOSCIENCES INC-A (SGMT) is expected to decline by -19.27% in the next year.